<?xml version="1.0" encoding="UTF-8"?>
<results title="sars_covid_2">
 <result pre="old and new pathogens that bear the risk of becoming" exact="pandemic" post="threats. In recent years, the rapid spread of severe"/>
 <result pre="of the world highly favor global spreading of pathogens. This" exact="pandemic" post="risk is further increased by the climate change that"/>
 <result pre="infections with a range of vector-borne diseases. The occurrence of" exact="pandemic" post="outbreaks in the past decades has clearly demonstrated the"/>
 <result pre="the past decades has clearly demonstrated the reality of global" exact="pandemic" post="threats. Human immunodeficiency virus ( HIV), the causative agent"/>
 <result pre="a variety of different species as well as their high" exact="genomic" post="variability additionally bears the constant risk of a zoonosis"/>
 <result pre="the human population. While the occurrence of a future influenza" exact="pandemic" post="is almost certain, it is impossible to predict the"/>
 <result pre="on the one hand, that led to a phase 6" exact="pandemic" post="alert declared by the WHO in 2009 but caused"/>
 <result pre="caused relatively mild symptoms and the 1918 influenza A H1N1" exact="pandemic" post="(&quot;Spanish flu&quot;) on the other hand, that resulted in"/>
 <result pre="coronavirus (CoV) that likely originated in bats ( 2, 3)." exact="SARS" post="CoV caused a global outbreak with 8,000 infected patients,"/>
 <result pre="in 26 countries ( 4). A notable aspect of the" exact="SARS" post="epidemic was the efficacy of containment measures that halted"/>
 <result pre="In 2012, a new coronavirus appeared in Saudi Arabia causing" exact="Middle East respiratory syndrome" post="(MERS). Like SARS CoV, the virus originated in bats"/>
 <result pre="in Saudi Arabia causing Middle East respiratory syndrome (MERS). Like" exact="SARS" post="CoV, the virus originated in bats and likely spread"/>
 <result pre="is only used in dengue-seropositive individuals. 6 In addition to" exact="pandemic" post="threats, the list of multi drug resistant (MDR) organisms"/>
 <result pre="of emerging pathogens represents one of the pivotal problems for" exact="pandemic" post="preparedness. Zoonoses present a constant threat to introduce a"/>
 <result pre="as was the case for HIV as well as for" exact="SARS" post="and MERS CoV. The outbreaks caused by pandemic influenza"/>
 <result pre="as for SARS and MERS CoV. The outbreaks caused by" exact="pandemic" post="influenza virus demonstrate the potential of a known pathogen"/>
 <result pre="is known and vaccine manufacturing technologies are established, like for" exact="pandemic" post="influenza vaccine, production capacity to meet peak demands during"/>
 <result pre="influenza vaccine, production capacity to meet peak demands during a" exact="pandemic" post="remains problematic. Thanks to efforts coordinated by the WHO,"/>
 <result pre="efforts coordinated by the WHO, the potential production capacity for" exact="pandemic" post="influenza vaccines in 2015 could in theory support the"/>
 <result pre="licensed vaccines would take 5–3 months between identification of a" exact="pandemic" post="influenza and vaccine distribution, which would give a pandemic"/>
 <result pre="a pandemic influenza and vaccine distribution, which would give a" exact="pandemic" post="virus ample time for global spread. Hence, technologies that"/>
 <result pre="amounts of vaccine are direly needed in the face of" exact="pandemic" post="threats. Efforts to meet these challenges are made by"/>
 <result pre="meet these challenges are made by monitoring viruses with high" exact="pandemic" post="potential and programs, most notably Coalition for Epidemic Preparedness"/>
 <result pre="Preparedness Innovations (CEPI), that finances and develops vaccines against likely" exact="pandemic" post="threats. Vaccine technologies The past decades have witnessed the"/>
 <result pre="the E1A and E1B (early transcript 1 A and B)" exact="genomic" post="region by an antigen expression cassette, thereby abolishing the"/>
 <result pre="the host cell for transcription and replication, the risk of" exact="genomic" post="integration exists, however, the vector predominantly remains episomal ("/>
 <result pre="as well as T cell responses with variations in the" exact="immune response" post="depending on the serotype employed ( 28). Replication-deficient Ad5,"/>
 <result pre="has established a highly stable vaccine for which reversion to" exact="pathogenicity" post="has never been observed ( 33). Moreover, MV is"/>
 <result pre="tropism of the virus ( 42). The amount of additional" exact="genomic" post="material stably accepted in the genome is 4–5 kb"/>
 <result pre="The route of administration affects the quality of the induced" exact="immune response" post="and the choice of application route thus depends on"/>
 <result pre="have been established, supporting the use of these technologies for" exact="pandemic" post="settings. Despite many advantages, several aspects have to be"/>
 <result pre="in the same vaccinee. Viral vector based vaccines in potential" exact="pandemic" post="settings using ebola virus as an example Viral vector"/>
 <result pre="based vaccines developed in the context of the recent Ebola" exact="pandemic" post="in order to highlight some of the advantages and"/>
 <result pre="most approaches were still in preclinical stages when the Ebola" exact="pandemic" post="emerged in 2014. Viral vector based vaccines against Ebolaviruses"/>
 <result pre="development of human vaccines. Upon the outbreak of the Ebola" exact="pandemic" post="in 2014, a new Ad5 based vaccine was developed"/>
 <result pre="infection, i.e., protein localizations such as presence in the plasma" exact="membrane" post="and modifications such as glycosylation patterns can be formed"/>
 <result pre="the nucleus of transfected cells poses the additional risk of" exact="genomic" post="integration into the host's chromosomes and the resulting threat"/>
 <result pre="DNA integration events upon IM injection in small animal models," exact="genomic" post="integration events were detectable following electroporation in mice ("/>
 <result pre="human cytokine to ensure vaccine safety. DNA vaccines in potential" exact="pandemic" post="settings Since the first experiments in the 1990 ("/>
 <result pre="have been tested for their efficacy to protect against recent" exact="pandemic" post="threats including HIV, MERS, Ebola, and Zika, some of"/>
 <result pre="safety profile; ~90% of the participants generated an Ebola-specific antibody" exact="immune response." post="Table 2 Clinical trials employing DNA vaccines in pandemic"/>
 <result pre="immune response. Table 2 Clinical trials employing DNA vaccines in" exact="pandemic" post="settings. Study start N Vaccine and delivery Outcome NCT00072605"/>
 <result pre="main target for neutralizing antibodies against influenza. In terms of" exact="pandemic" post="preparedness in DNA only vaccination strategies, Vical Inc. has"/>
 <result pre="a novel H1N1 influenza that originated in pigs and became" exact="pandemic" post="in humans in spring 2009 ( 100), efforts were"/>
 <result pre="the use of DNA-based vaccines for controlling a potential influenza" exact="pandemic" post="by employing DNA as an initial priming agent, followed"/>
 <result pre="flaviviruses, these approaches rely on the expression of the precursor" exact="membrane" post="and envelope (Env) (prM-E) proteins which are known to"/>
 <result pre="serves as a template for two positive-strand RNA molecules: the" exact="genomic" post="mRNA and a shorter sub-genomic mRNA. This sub-genomic mRNA"/>
 <result pre="take place. In this step, the plasma or endosomal lipid" exact="membrane" post="represents a barrier the mRNA vaccine has to cross"/>
 <result pre="efficiently as possible. In addition, the induction of an effective" exact="immune response" post="requires stimulation of the innate immune system by the"/>
 <result pre="type of immune cell and eventually leading to an enhanced" exact="immune response" post="against the antigen of choice. Several studies demonstrated that"/>
 <result pre="crucial impact on the quality and strength of the induced" exact="immune response." post="LNP-mRNA delivered intravenously (IV) primarily targets the liver ("/>
 <result pre="of administration has been shown to effectively induce a balanced" exact="immune response" post="including antibodies as well as Th1 type and cytotoxic"/>
 <result pre="the PRRs by mRNA vaccines results in a robust innate" exact="immune response" post="including production of chemokines and cytokines such as IL-12"/>
 <result pre="innate factors crucial for the induction of an effective adaptive" exact="immune response" post="against the encoded antigen. ID immunization with mRNA vaccines"/>
 <result pre="optimized mRNA vaccines, demonstrating a strong activation of the innate" exact="immune response" post="at the injection site and in the dLNs in"/>
 <result pre="critical role in antigen processing and presentation to elicit an" exact="immune response" post="against specific antigens. The transfected DCs express the mRNA-encoded"/>
 <result pre="immune responses following in vivo administration. Activation of the innate" exact="immune response" post="by RNA vaccines is potentially a double-edged sword. While"/>
 <result pre="response to the activation of PRRs can facilitate the adaptive" exact="immune response," post="it can lead to phosphorylation of eukaryotic translation initiation"/>
 <result pre="with the host-cell DNA, they avoid the potential risk of" exact="genomic" post="integration posed by DNA-based vaccines. Since mRNA vaccines represent"/>
 <result pre="with fast turnaround time. This is vital when facing a" exact="pandemic" post="threat requiring a rapid response platform capable of producing"/>
 <result pre="on the progression of an outbreak. RNA vaccines in potential" exact="pandemic" post="settings An increasing number of preclinical studies have shown"/>
 <result pre="vaccines to confer protection against various pathogens, including those with" exact="pandemic" post="potential ( 162, 173– 176). Self-amplifying mRNA vaccines encoding"/>
 <result pre="to induce immune responses and confer protection against pathogens with" exact="pandemic" post="potential such as ZIKV, EBOV and influenza. Importantly, some"/>
 <result pre="that were protective, conferred sterilizing immunity and restricted in utero" exact="transmission" post="of ZIKV in mice ( 162, 163). A Phase"/>
 <result pre="(Table 3). Table 3 Clinical trials employing RNA vaccines in" exact="pandemic" post="settings. Study start N Vaccine and delivery Outcome NCT03014089"/>
 <result pre="modified nucleotides, that encoded for HA proteins of the potentially" exact="pandemic" post="influenza A subtypes H10N8 or H7N9 ( 159). A"/>
 <result pre="broad applicability of this vaccine platform against pathogens posing potential" exact="pandemic" post="threats. Conclusions Pandemics such as HIV, Ebola, and Zika"/>
 <result pre="this technology. However, the potential for long term persistence and" exact="genomic" post="integration and the dependence on injection devices or electroporation"/>
 <result pre="the same established production process and facility. Their inability for" exact="genomic" post="integration and lack of persistence in the cells of"/>
 <result pre="Hoogen BG et al. . Aetiology: Koch's postulates fulfilled for" exact="SARS" post="virus. Nature ( 2003) 423: 240. 10.1038/423240a 12748632 4."/>
 <result pre="G . The 2015 global production capacity of seasonal and" exact="pandemic" post="influenza vaccine. Vaccine ( 2016) 34: 5410– 3. 10.1016/j.vaccine.2016.08.019"/>
 <result pre="5410– 3. 10.1016/j.vaccine.2016.08.019 27531411 17. Gilbert JA . Seasonal and" exact="pandemic" post="influenza: global fatigue versus global preparedness. Lancet Respir Med."/>
 <result pre="al. . Detection of integration of plasmid DNA into host" exact="genomic" post="DNA following intramuscular injection and electroporation . Gene Ther."/>
 <result pre="Z Enama ME et al. . Phase 1 study of" exact="pandemic" post="H1 DNA vaccine in healthy adults. PLoS ONE ("/>
 <result pre="Aberle SW Kofler RM Mandl CW . Humoral and cellular" exact="immune response" post="to RNA immunization with flavivirus replicons derived from tick-borne"/>
</results>
